Roche has agreed to purchase US-based Anadys Pharmaceuticals, a specialist in hepatitis C treatments, for around $230m in cash.

Roche’s attraction to Anadys is focused on the company’s ANA598 compound, currently being evaluated in combination with Roche’s Pegasys and Copegus treatments for hepatitis C.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Switzerland-based pharmaceutical firm is paying $3.70 a share, a 256% premium over the $1.04 closing price of Anadys on Friday October 14. The company’s board has advised other stockholders to follow the board’s lead and tender their shares.

Roche pharma research and early development head Jean-Jacques Garaud said: "Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure."

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now